Inclusion Criteria:  Provision of signed informed consent prior to any study-specific procedure; Weight of ≥40 kg (88 lb) and body mass index (BMI) ≥16 and ≤42 kg/m2; Very- high or high risk for CVD as defined in 2019 ESC/EAS Guidelines High-intensity statin (daily atorvastatin 40/80 or rosuvastatin 20/40) without other acceptable oral lipid lowering treatment plus diet; stable >4 weeks with LDL-C ≥85 mg/dL and triglycerides ≤400 mg/dL Women of childbearing potential (WOCBP) must continue using a highly effective form of birth control if sexually active Males whose partners are of CBP and not using a highly effective form of birth control will either be surgically sterile or agree to use the following forms of contraception, male or female condom with spermicide  Exclusion Criteria:  Prior or active clinical condition or acute and/or unstable systemic disease, including cancer, compromising patient inclusion or preclude completion of the study, at the discretion of the Investigator Homozygous FH non-high intensity statins, mipomersen, lomitapide, gemfibrozil, and bempedoic acid PCSK9 mAb within 4 weeks of screening or siRNA within 1 year Severe renal dysfunction, defined eGFR <30 ml/min Recent, within 3 months of screening, atherosclerotic event or intervention planned cardiac procedure NYHA class III or IV heart failure active liver disease uncontrolled diabetes defined as fasting glucose >200 mg/dL and HbA1c > 9% uncontrolled BP ≥180 mmHg systolic or ≥110 mmHg diastolic;